Dr. Mogal on the Role of Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis

Video

In Partnership With:

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, physician, Seattle Cancer Care Alliance, associate professor, Department of Surgery, University of Washington (UW) School of Medicine, program director, Regional Cancer Therapies, UW Medicine, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

Although not all patients with colorectal peritoneal carcinomatosis are amenable for cytoreductive surgery, well-selected patients can derive a significant benefit from the operation, Mogal says. Findings from the phase 3 PRODIGE 7 trial (NCT00769405) showed that although adding hyperthermic intraperitoneal chemotherapy with oxaliplatin to cytoreductive surgery didn’t improve overall survival, complete cytoreductive surgery led to satisfactory survival outcomes when used as a curative intervention in patients with peritoneal carcinomatosis from colorectal cancer.

As such, cytoreductive surgery is preferred compared with systemic chemotherapy alone in well-selected patients, Mogal explains. Patient selection should incorporate a discussion with the patient within a well-established and experienced cancer center that utilizes multidisciplinary tumor boards, Mogal concludes.

Related Videos
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center